Hsbc Holdings PLC Akebia Therapeutics, Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q4 2024

A detailed history of Hsbc Holdings PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 70,005 shares of AKBA stock, worth $134,409. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,005

Previous 54,973 27.34%

Holding current value

$134,409

Previous $72,000 80.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.26 - $2.13 $18,940 - $32,018	15,032 Added 27.34%	70,005 $130,000
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $51,674 - $85,208	54,973 New	54,973 $72,000
Q2 2022 Aug 11, 2022	SELL	$0.32 - $0.67 $22,114 - $46,301	-69,107 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $18,020 - $73,332	-25,028 Reduced 26.59%	69,107 $49,000
Q4 2021 Feb 11, 2022	BUY	$2.26 - $3.34 $124,464 - $183,943	55,073 Added 140.99%	94,135 $212,000
Q1 2021 May 14, 2021	SELL	$2.92 - $5.06 $38,141 - $66,093	-13,062 Reduced 25.06%	39,062 $132,000
Q4 2020 Feb 12, 2021	SELL	$2.22 - $3.78 $25,170 - $42,857	-11,338 Reduced 17.87%	52,124 $145,000
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $84,921 - $464,758	35,532 Added 127.22%	63,462 $158,000
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $14,600 - $29,726	-2,189 Reduced 7.27%	27,930 $379,000
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $17,482 - $43,663	4,264 Added 16.49%	30,119 $234,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $6.73 $457,112 - $973,534	-144,656 Reduced 84.84%	25,855 $168,000
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $605,314 - $920,759	170,511 New	170,511 $668,000

Others Institutions Holding AKBA

# of Institutions

128

Shares Held

63.3M

Call Options Held

50.6K

Put Options Held

203K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $353M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Akebia Therapeutics, Inc. Transaction History